Recombinant Fusion Proteins

Accession Number

DBCAT002953

Description

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Drugs

Drug	Drug Description
Tagraxofusp	A CD123-directed cytotoxin used to treat blastic plasmacytoid dendritic cell neoplasm.
Alefacept	A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
rGLP-1	Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2.
PRO-542	Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
Efanesoctocog alfa	A recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A.

Drugs & Drug Targets

Drug	Target	Type
Tagraxofusp	Interleukin-3 receptor subunit alpha	target
Alefacept	T-cell surface antigen CD2	target
Alefacept	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Alefacept	Low affinity immunoglobulin gamma Fc region receptor III-A	target
PRO-542	Free fatty acid receptor 4	target
Efanesoctocog alfa	Low-density lipoprotein receptor-related protein 2	target
Efanesoctocog alfa	Basement membrane-specific heparan sulfate proteoglycan core protein	target
Efanesoctocog alfa	Coagulation factor IX	target
Efanesoctocog alfa	Coagulation factor X	target